摘要
肺癌表面是全球死亡率的主要决定因素,分别占所有新发癌症病例和与癌症相关的死亡人数的13%和19%。分子特征分析来一个规律的趋势肺癌,以确定驱动突变。表皮生长因子受体(EGFR)是非小细胞肺癌(NSCLC)中最常见的驱动突变。焦油目前,EGFR突变型NSCLC的治疗方法已经成熟。EGFR突变在腺癌中的表达频率高于鳞状细胞癌。本文给出了一个详细的描述。EGFR突变型肺癌治疗方法的学术见解。本文概述了已批准的药物和临床药物的分子机制。这些药物尚未进入临床试验,但在治疗EGFR突变型肺癌方面显示出了广阔的前景。此外,本文还提供了相关梳理的简明信息。国际或单一疗法的临床试验,已经完成了各种途径。
关键词: 肺癌,表皮生长因子受体蛋白-酪氨酸激酶,单克隆抗体,泛素,热休克蛋白,组蛋白去乙酰化酶。
图形摘要
Current Cancer Drug Targets
Title:Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
Volume: 18 Issue: 8
关键词: 肺癌,表皮生长因子受体蛋白-酪氨酸激酶,单克隆抗体,泛素,热休克蛋白,组蛋白去乙酰化酶。
摘要: Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting 13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling has now become a regular trend in lung cancer to identify the driver mutations. Epidermal Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma. This article presents a detailed molecular insight of the therapeutic approaches for the treatment of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides concise information on relevant combinational or monotherapy clinical trials that have been completed for various approaches.
Export Options
About this article
Cite this article as:
Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer, Current Cancer Drug Targets 2018; 18 (8) . https://dx.doi.org/10.2174/1568009617666170623123848
DOI https://dx.doi.org/10.2174/1568009617666170623123848 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion
Mini-Reviews in Medicinal Chemistry The Chemopreventive Peptide Lunasin Inhibits d-Galactose- Induced Experimental Cataract in Rats
Protein & Peptide Letters Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Physiological and Non-Redundant Functions of PKC Isotypes in T Lymphocytes
Current Immunology Reviews (Discontinued) Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Editorial (Thematic Issue: Antitarget Therapies: New Frontiers in the Treatment of Cancer)
Anti-Cancer Agents in Medicinal Chemistry Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Current Pharmaceutical Biotechnology Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art
Current Cancer Therapy Reviews Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry